Diabetes Dialouge: Tidepool Updates, with Brandon Arbiter

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Brandon Arbiter, vice president of Business Development at Tidepool.

Tidepool, a nonprofit company driven by a mission of empowering people with diabetes, has stolen a number of headlines in recent years, beginning in January 2023 with the US Food and Drug Administration clearance of the Tidepool app and continuing through October 2024 with their announcement of a new data integration with continuous glucose monitoring manufacturer Abbott.

In the episode of Diabetes Dialogue, Arbiter explains the nonprofit company’s vision and driving mission—taking listeners on a deep dive into how Tidepool’s platform streamlines diabetes data management and enhances clinical workflows. Arbiter highlights Tidepool’s single sign-in feature, which reduces the burden on users by allowing seamless integration of CGM and insulin pump data, significantly improving clinical time efficiency and patient care. He also elaborates on the Big Data Donation Project, where patients can opt to donate anonymized data to support research—benefiting both nonprofit and commercial research partners.

Additionally, Arbiter shares Tidepool's new population health software, which integrates data from Dexcom and Libre CGMs, enabling clinicians to proactively monitor patients and identify those at risk based on time-in-range metrics. Arbiter also unveils Tidepool’s partnership with Lucile Packard Children's Health for a risk-stratified dashboard that guides proactive intervention. Lastly, Arbiter announces new features supporting device setting reviews, including access to historical pump and DIY Loop app settings, which will enhance personalized care by providing a fuller picture of patients’ device usage history.

Brandon Arbiter is an employee of Tidepool. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

1. Campbell P. Tidepool loop mobile app receives FDA Marketing Clearance. HCP Live. January 26, 2023. Accessed November 7, 2024. https://www.hcplive.com/view/tidepool-loop-mobile-app-receives-fda-marketing-clearance.
2. Tidepool. Tidepool Will Integrate With Abbott’s FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data. Business Wire. October 28, 2024. Accessed November 7, 2024. https://www.businesswire.com/news/home/20241024402862/en/Tidepool-Will-Integrate-With-Abbott%E2%80%99s-FreeStyle-Libre-Portfolio-for-Seamless-Cloud-to-Cloud-Data.